2013-09-10 10:54:53 - Recently published research from Global Markets Direct, "Psoriasis - Pipeline Review, H2 2013", is now available at Fast Market Research
Global Markets Direct's, 'Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/675176_psoriasis_pipeline_review_h2_2013.asp ..
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for
the indicated disease.
* A snapshot of the global therapeutic scenario for Psoriasis.
* A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Psoriasis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Johnson & Johnson, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Amgen Inc., Antares Pharma, Inc., GlaxoSmithKline plc, Echo Therapeutics, Inc., Stiefel Laboratories, Inc., XenoPort, Inc., ApoPharma, Piramal Healthcare Limited, Celltrion, Inc., Isotechnika Pharma Inc., Dr. Reddy's Laboratories Limited, LEO Pharma A/S, Ono Pharmaceutical Co., Ltd., Pfizer Inc., Teva Pharmaceutical Industries Limited, UCB Group, Cell Therapeutics, Inc., Sun Pharmaceutical Industries Limited, Incyte Corporation, 4SC AG, Addex Pharmaceuticals, AlbireoPharma, Can-Fite BioPharma Ltd., Karo Bio, Almirall, S.A., Basilea Pharmaceutica Ltd., Bionomics Limited, NexMed, Inc., NicOx SA, Nuvo Research Inc., Arena Pharmaceuticals, Inc., ProMetic Life Sciences Inc., Cytos Biotechnology AG, Biotie Therapies Corp., Provectus Pharmaceuticals, Inc., Uni-Bio Science Group Ltd., Synta Pharmaceuticals Corp., Panacea Biotec Limited, Sareum Holdings plc, Hybrigenics S.A., Advinus Therapeutics Pvt. Ltd., Affimed Therapeutics AG, Jenrin Discovery, Inc., Upsher-Smith Laboratories, Inc., Palau Pharma S.A, Phosphagenics Limited, Farmacija d.o.o. Tuzla, Foamix Ltd., Acceleron Pharma, Inc., Pieris AG, Phenex Pharmaceuticals AG, Argos Therapeutics, Inc., BioNumerik Pharmaceuticals, Inc., Anacor Pharmaceuticals, Inc., Allozyne, Inc., Coronado Biosciences, Inc., Gene Signal International SA., Catabasis Pharmaceuticals, Inc., Orphagen Pharmaceuticals, Inc., Ferrer Internacional S.A., TcL Pharma SAS, SARcode Corporation, Inimex Pharmaceuticals, Inc., Sosei Co. Ltd., Welichem Biotech Inc., Redox Pharmaceutical Corporation, Cellceutix Corporation, KaloBios Pharmaceuticals, Inc., Kinex Pharmaceuticals, LLC, SWITCH Biotech LLC, KAHR medical Ltd., Aphoenix, Inc., Covagen AG, Lycera Corp., Femta Pharmaceuticals, Inc., Fibrocell Sciences, Inc., Celtic Pharmaceutical Holdings L.P., AngioLab, Inc., Laila Pharmaceuticals Pvt. Ltd., GlycoMar Limited, Sigmoid Pharma., Advancell
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.